Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.

Kristian Reich Kenneth B Gordon Bruce E Strober April W Armstrong Megan MillerY K ShenY YouC HanY W YangPeter Foley Christopher Ernest Maitland Griffiths

Published in: The British journal of dermatology (2021)

Guselkumab maintains high levels of clinical response and improvement in patient-reported outcomes through 5 years in patients with moderate-to-severe psoriasis.

Keyphrases

patient reported outcomes
high intensity
early onset